( Pfizer Inc announced an agreement with ...)Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug,Health

Pfizer Inc announced an agreement with Schwarz Pharma AG under which it would be acquiring exclusive worldwide rights to fesoterodine, a new drug that can be a treatment option for an overactive bladder. //

"Overactive bladder is a debilitating condition that affects up to 100 million people around the world," said Karen Katen, vice chairman of Pfizer Inc and president, Pfizer Human Health. "We are excited about the potential of this new medicine to offer patients and their doctors a new alternative to existing therapies for managing the symptoms of overactive bladder." Schwarz had submitted an application for fesoterodine approval to both the US Food and Drug Administration and the European Medicines Evaluation Agency (EMEA) earlier this year. Initially Pfizer will pay $100 million to Schwarz Pharma. This amount can be increased provided the drug meets certain milestones. Royalties of both fesoterodine and Pfizer's Detrol product line for treatment of overactive bladder will be paid to Schwarz. Pfizer's Detrol LA is a leading drug that helps control involuntary bladder contractions and decreases the symptoms of urgency with or without frequency and incontinence. Since its introduction it has been prescribed to over 11 million patients worldwide.
'"/>




Page: 1
Related medicine news :

1. Pfizer unveils anti-smoking drug
2. The Effectiveness Of The Breast Cancer Drug By Pfizer
3. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
4. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
5. Pfizer’s Eraxis Approved By The FD
6. Pfizer Launches Viagra For Lung Disease In UK
7. Pfizer Commences Its Advertising for Celebrex with All the Warnings
8. FDA Approves Pfizer’s Anti-smoking Dru
9. Pfizer vouches safety of long-term inhaled insulin.
10. NICE Setback Rules for Pfizers Inhaled Insulin
11. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo